Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.

CNBC

United States

Amgen stock falls as analysts mull over weight loss drug’s bone density data

Ad Fontes Media

All Sides

Media Bias/Fact Check

Roberts family

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity candidate MariTide. Read more here.

Seeking Alpha

Amgen stock slips amid obesity drug risk (update) (AMGN:NASDAQ)

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
The data, spotted by an analyst at Cantor Fitzgerald, focused on concerns about potential side effects with the drug, called MariTide. Once they were shared widely in an…

BizToc

A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value

Omar Marques | Lightrocket | Getty ImagesShares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide.One analyst said the additional data suggests a new potential safety risk tied to the drug. But others said the share move was an overreaction, and that more data on a larger group of patients is needed.Amgen did not immediately respond to a…

Jingletree

The company's stock fell 7% based on a single analyst note about unverified data on its lead obesity candidate.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. One analyst said the additional data suggests a new potential safety risk tied to the drug. But others said the share move was an overreaction, and that more data on a larger group of patients is needed. Amgen did not immediately respond to a request for comment on the data  The d…

Stockxpo - A professional network of traders, investors and analysts

On Tuesday, Amgen’s lead obesity candidate, MariTide, faced concerns about potential side effects after hidden data showing loss of bone mineral density in study participants was uncovered. An analyst at Cantor Fitzgerald found the data, which led to a $12 billion drop in market value for Amgen as the news spread. This incident highlighted the stock’s vulnerability ahead of a critical readout of the therapy. The hidden tabs with concerning resul…

Amgen stock falls as analysts mull over weight loss drug’s bone density data

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics